News from diamyd medical ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 16, 2020, 03:17 ET Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes

Diamyd Medical and the Critical Path Institute (C-Path) are proud to announce their collaboration to significantly improve the scientific community's ...

Dec 03, 2020, 03:00 ET Diamyd Medical with MainlyAI and KTH awarded VINNOVA funding for AI driven sustainable production

Diamyd Medical together with MainlyAI AB and KTH Royal Institute of Technology have been awarded funding by the Swedish Governmental Innovation...

Sep 16, 2020, 07:03 ET Diamyd Medical invites to a webcast presentation on September 17 on the results from DIAGNODE-2

Diamyd Medical announced earlier this week that the diabetes vaccine Diamyd® has demonstrated significant effect in a subgroup which covers about...

Sep 14, 2020, 11:38 ET Phase IIb topline results demonstrate a significant treatment effect of Diamyd® in a previously identified genetic subgroup of individuals with type 1 diabetes

Diamyd Medical today announced the topline results from the placebo-controlled Phase IIb trial DIAGNODE-2, where the diabetes vaccine Diamyd®...

Aug 05, 2020, 03:20 ET Diabetologia publishes results highlighting efficacy of the diabetes vaccine Diamyd® in genetically defined subgroups of type 1 diabetes

Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]) has published results from a meta study that demonstrates a...

Jun 24, 2020, 02:54 ET Diamyd Medical AB (publ) Quarterly Report III 19/20 -September 2019 - May 2020, Fiscal year 2019/2020

Developing therapies for type 1 diabetes Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. Further...

May 04, 2020, 07:25 ET Promising Findings From the First Part of a Clinical Trial With Remygen®

The initial safety and dose escalation part of the Phase I/II trial ReGenerate-1 with Remygen® in individuals with long-term type 1 diabetes today...

Apr 24, 2020, 07:00 ET Japan Grants Patent for Intralymphatic Administration of the Diabetes Vaccine Diamyd®

The patent now granted by the Japan Patent Office is valid until 2035. Diamyd Medical recently announced the grant of the corresponding patent in...

Apr 16, 2020, 13:01 ET Diamyd Medical Opens up for Vaccine Manufacturing in Umeå, Sweden

A new manufacturing facility is being set up in Umeå by Diamyd Medical. The first priority of the new site is to receive the process technology for...

Dec 20, 2019, 11:50 ET Positive Top-line Results From I/II Trial With Intralymphatic Diamyd®

Diamyd Medical announced today, when all 12 patients have been followed throughout the 30-month period in the open-label trial DIAGNODE-1, that the...

Dec 12, 2019, 15:46 ET Significant Effect of Diamyd® in Type 1 Diabetes Shown in a New Comprehensive Analysis of Previous Phase III and Phase II Trials

Diamyd Medical announces that a new analysis based on data from more than 530 individual patients from previous phase III and II trials in Europe and ...

Oct 15, 2019, 06:00 ET Diamyd Medical Enters Agreement for Intralymphatic Diamyd ® Trial in LADA

The agreement with the Norwegian University of Science and Technology in Trondheim (NTNU) refers to a first, investigator initiated clinical Phase II ...

Sep 09, 2019, 09:14 ET Feasibility Study Supports the use of Intralymphatic Injections of Diamyd®

A feasibility study performed as a Master Thesis at Uppsala University and supervised by Diamyd Medical, supports the use of ultrasound guided...

Jun 04, 2019, 02:36 ET New Interim Report at 30 Months and After Extra Injection Supports Long-term Effect of Intralymphatic Diamyd®

The first seven patients that have now been followed for the entire 30-month period in DIAGNODE-1 continue to show a positive clinical course and are ...

May 29, 2019, 09:07 ET The Swedish Medical Products Agency Approves New Treatment Arm With Remygen® and Alprazolam in Phase I/II Trial ReGenerate-1

The approval by the Swedish MPA entails that ReGenerate-1, with Diamyd Medical's GABA-based investigational drug Remygen®, will be expanded from the...

Mar 26, 2019, 03:45 ET Diamyd Medical Announces Strategic Activities for 2019 and 2020

With experience from clinical trials in more than 1,000 patients with the diabetes vaccine Diamyd®, preparations for a Conditional Marketing...

Dec 06, 2018, 02:31 ET Diamyd Medical Raises SEK 58.4 Million in Funds Through Redemption of Warrants

During 1 to 30 November 2018, holders of warrants of series TO 1 B and TO 2 A of Diamyd Medical AB have been able to subscribe for shares through...

Oct 23, 2018, 02:52 ET New Immunological Results That Support Intralymphatic Treatment With Diamyd® to be Presented at the Immunology of Diabetes Society Congress

New results of intralymphatic treatment with the diabetes vaccine Diamyd® indicate the induction of a long-term immune response that supports the...